Kim S, Kim SH, Kim BK, et al. - Recently, a randomized phase 3 study conducted at 154 sites in 20 countries demonstrated lenvatinib as non‐inferior to sorafenib in terms of overall survival (OS). In Korean patients with unresectable HCC, treatment outcomes and the safety of lenvatinib vs sorafenib were determined, as were independent predictors of poor outcomes, including shorter progression‐free survival (PFS) and OS in this study. Researchers assessed patients with advanced HCC who were provided treatment with lenvatinib or sorafenib at Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine between October 2018 to October 2019. Outcomes revealed significantly longer PFS for patients treated with lenvatinib vs sorafenib. In addition, the two groups had no significant differences in mortality rates, which suggests lenvatinib is non‐inferior to sorafenib in terms of OS.